Business Wire

Thales Laser on Mars 2020 Mission: Three Days to Touchdown

Share

On 18 February, the Perseverance rover — a key component of the Mars 2020 mission — will touch down on the Red Planet after a long seven-month voyage. SuperCam, one of seven strategic onboard instruments, is a powerful combination of technologies designed to analyse, characterise and select Martian rock samples. SuperCam is the result of close collaboration between Los Alamos National Laboratory (LANL) in the United States and the astrophysics and planetology research institute in France (IRAP, CNRS / CNES / Université Toulouse III - Paul Sabatier), with contributions from the University of Hawaii and the University of Valladolid in Spain. The Mast Unit, the French part of SuperCam located at the top of the rover’s mast, was designed and built by a consortium of French laboratories1 from CNRS, universities and entities under the scientific lead of the IRAP team and under the responsibility of CNES, the French space agency. The laser supplied by Thales is a key part of the Mast Unit.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210215005423/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Credits: NASA

In 2012, Curiosity landed on Mars equipped with the first high-power laser to operate on the surface of another planet, a laser designed and developed by Thales for the ChemCam instrument. The ChemCam laser has been operating faultlessly for over eight years and has fired close to 855,000 shots to date as Curiosity has made its 24-kilometre trek across the surface of the Red Planet. Data from ChemCam has already helped to prove that conditions on Mars were once suitable for microbial life.

The SuperCam instrument, a new and more powerful version of ChemCam, is designed to take Mars exploration to a new level. Like ChemCam, the SuperCam laser will use an infrared beam to heat material to a temperature of around 10,000°C and vaporise it — a method called laser induced breakdown spectroscopy. Coupled with a special camera, this makes it possible to determine the chemical composition of Martian rock samples by measuring the colours of light in the plasma created.

Unlike ChemCam, however, the SuperCam laser can also emit a green laser beam, which will help determine the molecular composition of surface materials. This green beam excites the chemical bonds in samples and produces a different signal according to their various linked components. This analysis technique, known as Raman spectroscopy, will be tested for the first time on Mars and will enable scientists to detect any markers of life. The green laser will also be used to induce fluorescence in mineral and organic compounds, allowing scientists to determine their constituent components with greater accuracy.

“We’re proud to have provided NASA with the first two lasers to operate on Mars. The Mars 2020 mission is a decisive step forward in the study of the Red Planet and preparations for future expeditions. SuperCam, the ‘eyes’ of Perseverance, is the result of close collaboration between partners across the international scientific community. Thales's SuperCam laser delivers unrivalled performance and will enable Perseverance to perform its exploration mission throughout its time on the surface of Mars.” Christophe Salomon, Executive Vice President, Land and Air Systems

About Mars 2020

The goal of the Mars 2020 mission is to study the Red Planet’s surface, search for signs of past life, take rock and dust samples at selected sites and store them for retrieval by the future Mars Sample Return (MSR) mission, which will be conducted jointly with the European Space Agency. Thales Alenia Space is closely involved in the MSR mission.

The Mars 2020 mission is designed to gather the necessary knowledge and test the technologies that will be vital for future human expeditions to the Red Planet.

How to produce oxygen from the Martian atmosphere? What resources are available? Is there water beneath the surface, for example? How to improve landing techniques and characterise weather conditions, dust levels and other environmental conditions that could affect the life and work of future astronauts on Mars? These are just some of the questions the Perseverance mission will seek to answer.

About Thales lasers

For more than 35 years, Thales has been a world leader in design, development and manufacturing of high energy nanosecond lasers for industrial applications and the most powerful ultra-short Ti:Sa femtosecond laser systems for leading scientific applications with peak power up to 10 petawatts.

Thales provides the most reliable and easy-to-use products, a unique combination of technological expertise and robustness for implementation into industrial applications that require highest availability such as laser annealing, laser lift-off, laser shock peening and cutting of composites for various industries such as aerospace, microelectronics, flat panel displays and many others. Thales provides also a full range of services, which are optimized to support each customer.

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months). Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.

PLEASE VISIT

Thales Group

[1] The Irap ; the Laboratoire d’études spatiales et d’instrumentation en astrophysique (LESIA, Observatoire de Paris-PSL/CNRS/SU/Université de Paris) ; the Laboratoire d’astrophysique de Bordeaux (LAB, CNRS/Université de Bordeaux) ; the Laboratoire « atmosphères et observations spatiales » (LATMOS, CNRS/SU/UVSQ) ; l’Observatoire Midi-Pyrénées (OMP, CNRS/IRD/Météo-France/Université de Toulouse III – Paul Sabatier) ; the Institut d’astrophysique spatiale (IAS, CNRS/Université Paris-Saclay).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS
Thales, Media Relations
Group and Innovation
Alice Pruvot
+33 (0)7 70 27 11 37
alice.pruvot@thalesgroup.com

Thales Alenia Space, Media Relations
Sandrine Bielecki
+33 (0)4 92 92 70 94
sandrine.bielecki@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 14:47:00 EET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting me

SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 14:00:00 EET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which

Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 12:15:00 EET | Press release

Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassado

Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release

3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad

Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 08:00:00 EET | Press release

NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye